HER2-Positive Cancer Clinical Trials: Monitor the Full HER2 Landscape Daily

Why HER2-positive cancer trial monitoring matters in 2026

HER2 (ERBB2) overexpression or amplification was first validated as a therapeutic target in breast cancer with the approval of trastuzumab. Since then, HER2 has become one of oncology's most productive drug targets — and also one of its most crowded. The competitive landscape is evolving faster than ever, driven by two forces: the expansion of HER2-targeting agents into new tumor types, and the redefinition of what counts as a "HER2-positive" patient.

Trastuzumab deruxtecan (T-DXd, Enhertu, AstraZeneca/Daiichi Sankyo) has been the dominant story of the last three years. Its DESTINY trial series established activity not just in HER2-positive breast cancer, but also in HER2-low (IHC 1+ or IHC 2+/ISH-negative) and HER2-ultralow (IHC 0 with faint incomplete staining) breast cancer — expanding the addressable population from ~15–20% of breast cancer patients to potentially 60% or more. The same framework is being applied in gastric, colorectal, biliary, endometrial, and non-small cell lung cancers.

Key signals that HER2 competitive intelligence professionals track:

• New T-DXd combination trials testing HER2-low eligibility and IO combinations (rilvegostomig + T-DXd, Phase 3: NCT06467357)
• Phase 1 dose-escalation studies for next-generation HER2-targeting ADCs competing with T-DXd on payload, linker, and DAR
• HER2-targeted trials in non-breast tumor types — gastric, colorectal, endometrial, biliary tract — each expanding rapidly
• Tucatinib (Pfizer/Seagen) Phase 3 programs in HER2+ breast cancer and HER2-amplified colorectal cancer
• Bispecific antibodies targeting dual HER2 epitopes (zanidatamab) or HER2 paired with HER3
• Protocol amendments on pivotal trials — enrollment holds, dose adjustments, endpoint modifications

The T-DXd DESTINY trial series — 11 active Phase 3 programs

No single asset has more active Phase 3 HER2 trials than trastuzumab deruxtecan. AstraZeneca and Daiichi Sankyo have built one of oncology's most ambitious clinical programs, spanning five tumor types with multiple indication-specific registrational trials:

NCT ID	Indication	Key Comparison	Status
NCT04784715	HER2+ Breast Cancer (1L)	T-DXd ± pertuzumab vs. THP	Recruiting
NCT04494425	HER2-low Breast Cancer	T-DXd vs. investigator's choice	Active
NCT04739761	Breast Cancer + Brain Mets	T-DXd ± brain-specific cohort	Active
NCT05113251	HER2+ Breast Cancer	T-DXd sequence vs. THP	Recruiting
NCT05950945	HER2-low Breast Cancer (HR+)	T-DXd in HR+/HER2-low pts	Recruiting
NCT04704934	HER2+ Gastric Cancer	T-DXd vs. ramucirumab + paclitaxel	Active
NCT06899126	HER2+ NSCLC (1L)	T-DXd + pembro + chemo	Recruiting
NCT07022483	Endometrial Cancer	T-DXd vs. standard of care	Recruiting
NCT06989112	Endometrial Cancer (DESTINY-E01)	T-DXd Phase III	Recruiting
NCT06467357	Biliary Tract Cancer	T-DXd + rilvegostomig vs. SoC	Recruiting
NCT06819007	Ovarian Cancer	T-DXd + bevacizumab vs. bev	Recruiting

Each of these trials represents a potential new indication label for Enhertu — and a competitive signal for every other company with a HER2-targeting asset. Monitoring protocol amendments, enrollment updates, and recruitment holds across all 11 programs simultaneously is not practical without automated alerts.

HER2-low and HER2-ultralow: redefining the patient population

The most commercially significant development in HER2 targeting since trastuzumab approval is the reclassification of "HER2-low" as a distinct therapeutic population. Historically, HER2 IHC 1+ and IHC 2+/ISH-negative tumors were considered HER2-negative and excluded from HER2-directed therapy. DESTINY-Breast06 (NCT04494425) changed this by demonstrating PFS benefit of T-DXd in the HER2-low population. DESTINY-Breast06 extended this further into HER2-ultralow (IHC 0 with incomplete staining).

The practical implication: the addressable market for HER2-targeting ADCs in breast cancer has expanded from ~20% (traditional HER2+ IHC 3+ or ISH+) to potentially 55–60% of all metastatic breast cancer patients. This is driving a wave of Phase 1 and Phase 2 trials for competitor ADCs that are designing their eligibility criteria to capture HER2-low patients from the outset — early-stage intelligence that requires continuous trial monitoring to track.

Zanidatamab: the leading next-generation bispecific

Zanidatamab (Jazz Pharmaceuticals), a bispecific antibody targeting two non-overlapping HER2 domains (domain II and domain IV), has advanced the furthest among post-trastuzumab HER2-targeting biologics. Three active Phase 3 trials define its clinical program:

• NCT05152147 — HER2+ gastric/GEJ cancer (1L), chemotherapy ± zanidatamab ± pembrolizumab
• NCT06282575 — HER2-amplified biliary tract cancer, zanidatamab + standard of care
• NCT06435429 — HER2+ metastatic breast cancer, zanidatamab vs. trastuzumab (head-to-head Phase 3)

The Phase 3 head-to-head comparison with trastuzumab (NCT06435429) is particularly significant — positive results would position zanidatamab as a backbone replacement rather than add-on, with implications for every trastuzumab-containing combination regimen globally. Monitoring enrollment and amendment activity on this trial is essential for companies with trastuzumab biosimilar or HER2-targeting combination programs.

HER2 in non-breast tumor types

Gastric and gastroesophageal junction cancer

HER2 is amplified in approximately 15–20% of gastric and GEJ adenocarcinomas. The TOGA trial established trastuzumab + chemotherapy as the first HER2-directed standard of care in gastric cancer in 2010. The current landscape is more complex: DESTINY-Gastric02 (NCT04704934) is establishing T-DXd as second-line standard, multiple zanidatamab combinations are in Phase 3, and novel ADCs from Chinese sponsors (disitamab vedotin/RC48, SHR-A1811) are generating competitive Phase 3 data. Monitoring HER2+ gastric cancer trials requires tracking a global pipeline with active programs in Japan, Korea, China, and the US simultaneously.

HER2-amplified colorectal cancer

HER2 amplification occurs in approximately 2–5% of colorectal cancer patients (enriched in RAS/BRAF wild-type disease) and defines a population with minimal benefit from EGFR-targeting antibodies but sensitivity to HER2-directed therapy. Two active Phase 3 trials are establishing the standard: tucatinib + trastuzumab + mFOLFOX6 (NCT05253651, Pfizer/Seagen) and T-DXd combinations. The tucatinib Phase 3 in colorectal cancer is one of the most watched enrollment trackers in GI oncology — enrollment pace signals competitive position in a small but well-defined patient population.

HER2-mutant non-small cell lung cancer

HER2 exon 20 insertions account for approximately 3% of NSCLC cases and are now targetable with two approved agents: fam-trastuzumab deruxtecan (T-DXd) and zongertinib (BI-1810631, Boehringer Ingelheim). Zongertinib (Beamion LUNG-2: NCT06151574, Beamion LUNG-3: NCT07195695) is in Phase 3 with the clearest oral TKI profile in HER2-mutant NSCLC, with pivotal data expected in 2026. The SHR-A1811 (jiangsu HengRui) Phase 3 in HER2-mutant NSCLC (NCT06430437) adds a Chinese ADC competitor. DataLookout monitors all three programs simultaneously.

HER2-positive endometrial and biliary tract cancer

HER2 overexpression occurs in 25–30% of serous endometrial carcinomas and 15–20% of biliary tract cancers — two tumor types that historically had few targeted therapy options. DESTINY-Endometrial01 (NCT06989112) and a second T-DXd endometrial Phase 3 (NCT07022483) represent the leading regulatory programs in endometrial HER2+ disease. The zanidatamab biliary tract Phase 3 (NCT06282575) is the most advanced HER2-targeted program in biliary cancer, with HER2 amplification defined as a key predictive biomarker via ctDNA and tissue sequencing. Both tumor types are underrepresented in standard CI dashboards but increasingly important as approvals expand the HER2-positive universe.

Selected active Phase 3 HER2 trials

NCT ID	Agent	Sponsor	Indication	Status
NCT05132582	Tucatinib + THP	Pfizer/Seagen	HER2+ Breast Cancer (1L)	Recruiting
NCT05253651	Tucatinib + trastuzumab + mFOLFOX6	Pfizer/Seagen	HER2+ Colorectal Cancer	Recruiting
NCT06151574	Zongertinib	Boehringer Ingelheim	HER2-mutant NSCLC (Beamion LUNG-2)	Recruiting
NCT07195695	Zongertinib	Boehringer Ingelheim	HER2-mutant NSCLC (Beamion LUNG-3)	Recruiting
NCT06057610	SHR-A1811	Jiangsu HengRui	HER2+ Breast Cancer	Recruiting
NCT06430437	SHR-A1811	Jiangsu HengRui	HER2-mutant NSCLC (1L)	Recruiting
NCT06018337	DB-1303/BNT323	DualityBio/BioNTech	HER2-low/ultralow Breast Cancer	Recruiting
NCT07413939	RO7771950 vs. tucatinib	Hoffmann-La Roche	HER2+ Breast Cancer	Recruiting

What DataLookout monitors for HER2-positive cancer

DataLookout pulls directly from the ClinicalTrials.gov API every day. For a HER2-positive cancer watch profile, configure:

• Condition keywords: "HER2 positive", "HER2-positive cancer", "HER2+ breast cancer", "HER2+ gastric cancer", "HER2 low", "HER2 amplified", "ERBB2", "HER2-ultralow", "HER2-mutant NSCLC"
• Intervention keywords: "trastuzumab deruxtecan", "T-DXd", "zanidatamab", "tucatinib", "zongertinib", "pertuzumab", "HER2-DXd", "SHR-A1811", "margetuximab"
• Phase filter: Phase 1 only (early pipeline), Phase 2/3 (late-stage), or all phases
• Sponsor filter: Industry-sponsored only (competitive intelligence) or all sponsors including academic
• Status filter: Recruiting only, all active studies, or any status

Because HER2 spans multiple tumor types, many users set up separate profiles by indication — one for HER2+ breast cancer, one for HER2+ gastroesophageal cancers, one for HER2-mutant NSCLC — to keep digests focused and actionable.

How it compares to ClinicalTrials.gov RSS alerts

ClinicalTrials.gov does have a basic RSS/email notification system, but it has significant limitations for professional use:

• No phase filtering — Phase 1 first-in-human studies appear alongside major Phase 3 trials
• No sponsor type filtering — academic, NIH, and industry trials are mixed together
• No clear labeling of "new" vs. "updated" trials — everything looks the same
• No support for multiple simultaneous search profiles
• Difficult to set up and manage for non-technical users

DataLookout delivers filtered, labeled, and organized alerts — the intelligence layer on top of the raw data.

Who uses HER2 trial monitoring

Competitive intelligence teams at HER2-focused oncology companies

The HER2 space has more active Phase 3 programs than almost any other oncology target. CI teams at companies with HER2 assets — whether ADCs, bispecifics, TKIs, or combination regimens — need comprehensive daily coverage to track competitor trial openings, protocol amendments that signal dose-optimization decisions, and early-phase expansions into new tumor types. A competitor posting a new Phase 1 expansion cohort in HER2-low colorectal cancer may not make a press release for months, but it will appear on ClinicalTrials.gov within days.

Business development teams evaluating HER2-targeted assets

BD teams at large pharma companies looking to in-license next-generation HER2 programs use trial monitoring to identify interesting early-stage programs before they generate Phase 2 data and attract competitive bidding. The HER2-low expansion thesis has created a new BD angle: smaller biotechs building HER2-low eligibility into their ADC programs from Phase 1 are potentially more attractive partnership candidates for companies seeking to compete with T-DXd. Monitoring which programs are taking that approach gives BD teams a head start on sourcing conversations.

Medical affairs and evidence generation teams

Medical affairs teams at HER2-targeting companies use trial monitoring to track the investigator-initiated study (IIS) landscape — academic and NCI-sponsored trials testing their approved agents in new combinations, sequencing strategies, or patient subgroups. These studies generate evidence that informs label discussions, payer negotiations, and post-marketing strategy.

Frequently asked questions

How current is the HER2-positive cancer trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track HER2-low separately from HER2-positive (IHC 3+/ISH+)?

Yes — you can configure separate profiles with different keyword sets. A HER2-low specific profile might use keywords like "HER2-low", "HER2 low", "IHC 1+", or "HER2-ultralow" to capture trials explicitly designed for that population. A standard HER2-positive profile catches trials using traditional HER2+ eligibility criteria. Running both profiles simultaneously is supported on the Starter plan ($29/month) and Pro plan ($99/month, unlimited profiles).

Does DataLookout cover international trials?

ClinicalTrials.gov includes trials conducted internationally — international trials from Japanese, Korean, Chinese, and European sponsors with global sites are all captured. Given the large volume of HER2 trials from Chinese ADC companies (HengRui, BeiGene, DualityBio, Sichuan Baili), international coverage is particularly important in this indication.

How do I filter for specific HER2 mechanisms (TKI vs. ADC vs. bispecific)?

Use intervention keyword filters. For ADCs: "trastuzumab deruxtecan", "T-DXd", "SHR-A1811", "disitamab vedotin". For TKIs: "tucatinib", "neratinib", "lapatinib", "zongertinib", "pyrotinib". For bispecifics: "zanidatamab", "KN026", "HLX22". This lets you separate different mechanism classes into dedicated watch profiles.